Recombinant Human Breast Cancer Metastasis-Suppressor 1 (BRMS1) Protein (GST)

Name: Recombinant Human Breast Cancer Metastasis-Suppressor 1 (BRMS1) Protein (GST)
Brand: Beta LifeScience
SKU: BLC-08441P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Breast Cancer Metastasis-Suppressor 1 (BRMS1) Protein (GST) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q9HCU9
Target Symbol	BRMS1
Synonyms	AV003220; AW554636; Breast cancer metastasis suppressor 1; Breast cancer metastasis-suppressor 1; BRMS1; BRMS1_HUMAN; DKFZp564A063 ; MGC95128
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-GST
Target Protein Sequence	MPVQPPSKDTEEMEAEGDSAAEMNGEEEESEEERSGSQTESEEESSEMDDEDYERRRSECVSEMLDLEKQFSELKEKLFRERLSQLRLRLEEVGAERAPEYTEPLGGLQRSLKIRIQVAGIYKGFCLDVIRNKYECELQGAKQHLESEKLLLYDTLQGELQERIQRLEEDRQSLDLSSEWWDDKLHARGSSRSWDSLPPSKRKKAPLVSGPYIVYMLQEIDILEDWTAIKKARAA
Expression Range	1-235aa
Protein Length	Partial
Mol. Weight	54.3kDa
Research Area	Apoptosis
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma.
Subcellular Location	Nucleus. Cytoplasm. Note=Predominantly nuclear.
Protein Families	BRMS1 family
Database References	HGNC: 17262 OMIM: 606259 KEGG: hsa:25855 STRING: 9606.ENSP00000396052 UniGene: PMID: 30365131 overexpression of miR-3200-5p significantly decreased BRMS1 levels and promoted OS cell invasion and migration, while depletion of miR-3200-5p significantly increased BRMS1 levels and inhibited OS cell invasion and migration. Study revealed that miR-3200-5p may be a critical regulator of OS cell invasiveness. PMID: 29890825 Low BRMS1 expression is associated with Hepatocellular carcinoma. PMID: 29295726 Low BRMS1 expression is associated with high metastatic capacity of breast cancer. PMID: 29970691 High BRMS1 Expression is associated with Metastases and recurrence in Lung Adenocarcinoma. PMID: 29097253 The results showed that reduction in the breast cancer metastasis suppressor 1 [BRMS1] expression level was linked directly to clinico-pathological features of breast cancer significantly. The loss of expression or reduced levels of BRMS1 is potentially a strong indicator of the metastatic capacity of breast cancer with poor prognosis. PMID: 28533425 The RAS-related nuclear protein ((P) ran), breast cancer metastasis suppressor 1 ((P) brms1) and minichromosome maintenance complex component 5 ((P) mcm5) promoters have the specificity and strength needed for cancer-specific expression-targeted gene therapy. PMID: 27140445 we identify a therapeutically exploitable posttranslational mechanism by which CK2alpha-mediated degradation of BRMS1 promotes metastases in lung cancer PMID: 26980766 our study characterized DAPK1 as a novel transcriptional target of BRMS1. Transcriptional activation of DAPK1 might be another important mechanism accounting for the metastasis suppressive activity of BRMS1. PMID: 28339067 BRMS1 promoter methylation and aberrant protein expression seem to be related to high-risk types of human papilloma virus-induced carcinogenesis in uterine cervix. PMID: 28381193 miR-346 promotes migration and invasion of nasopharyngeal carcinoma cells via targeting BRMS1. PMID: 27501413 A novel link has been discussed between CDK2 expression and cell migration by characterizing the CDK2-mediated phosphorylation of BRMS1. PMID: 26730572 Phosphorylation of BRMS1 by CDK2 regulates the migration of tumor cells. PMID: 26771717 Data show that Cullin3 exerts its function through promoting breast-cancer metastasis suppressor 1 (BRMS1) protein degradation, which was associated with epithelial-mesenchymal transition (EMT), migration and invasion. PMID: 26544623 The studies reviewed here with respect to BRMS1 structure, cellular effects, intracellular signaling, and clinical value consolidate the importance of BRMS1 in the development of metastasis. PMID: 26328523 Aberrant methylation of BRMS1 frequently occurs in the down-regulation of BRMS1 in triple negative breast cancer and that it may play a role in the metastasis of breast cancer. PMID: 26617826 the present study demonstrates a mechanical cascade of BRMS1 suppressing cancer cell invasion through downregulating HIF-1alpha transcript and consequently reducing Snail and TWIST1 expression. PMID: 26520789 MRTF-A and STAT3 synergistically recruited DNMT1 to hypermethylate the promoter of BRMS1 and affect the expression of BRMS1.MRTF-A and STAT3 promote breast cancer cell migration via hypermethylating BRSM1. PMID: 25854163 BRMS1 expression in human breast cancer is negatively correlated with JARID1C expression. Our results, for the first time, portray a pivotal role of JARID1C in regulating metastatic behaviors of breast cancer cells PMID: 26182878 high expression of BRSM1 in rectal cancer plays an essential role in tumor progression PMID: 24748145 loss of BRMS1 promotes malignant phenotypes that are dependent on NF-kappaB-dependent regulation of Twist1 PMID: 25368381 BRMS1 is a key regulator required to maintain a cellular morphology and cytoskeletal architecture consistent with an epithelial phenotype. PMID: 24763730 BRMS1 overexpression inhibited glioma cell invasion. PMID: 24879377 BRMS1-expressing cells remained rounded. PMID: 24000122 Silencing of BRMS 1 significantly induced the expression of NF-kappaB subunit, p65, uPA, and OPN proteins PMID: 24984534 Methylation of BRMS1 promoter in cfDNA isolated from plasma of NSCLC patients provides important prognostic information and merits to be further evaluated as a circulating tumour biomarker. PMID: 24642624 Data define BRMS1 promoter methylation in primary breast tumors and associated circulating tumor cells. PMID: 23744981 Low levels of BRMS1 were observed in patients with high-grade tumors, in patients with distant metastasis in breast cancer. PMID: 24596389 BRMS1 SNP rs1052566 heterozygous individuals were more likely to have node-positive breast tumors. PMID: 23771732 Report BRMS1 transcript variant which regulates heptocellular carcinoma apoptosis and growth. PMID: 23643861 Authors observed that residues 85 to 98 might be important in defining the oligomerization state of the BRMS1 N-terminal coiled coil. PMID: 23500495 The C-terminal putative nuclear localization sequence (NSL2) of BRMS1 is necessary for metastasis suppression. PMID: 23390556 Data suggest that low expression of the metastasis suppressor BRMS1 may be an independent prognostic factor for poor prognosis in nasopharyngeal carcinoma (NPC) patients. PMID: 22931099 The expression of BRMS1 protein in supraglottic cancer is significantly decreased. BRMS1 gene promotor methylation is related with down-expression of BRMS1 protein. PMID: 23167184 Data indicate that mutation of E3 ligase motif not only abolishes BRMS1-induced p300 polyubiquitination and degradation, but importantly, dramatically reduces the metastasis suppressor function of BRMS1. PMID: 23269275 BRMS1 sensitizes HCC cells to apoptosis through suppressing OPN expression PMID: 22927944 The loss of BRMS1 expression may be involved in the development and progression of nasal and paranasal sinus carcinomas. PMID: 22239051 Loss of breast cancer metastasis suppressor 1 promotes ovarian cancer cell metastasis by increasing chemokine receptor 4 expression. PMID: 22200669 high level of expression and lack of promoter methylation are associated with better overall survival in non-small cell lung cancer patients PMID: 21726917 These results suggest that the novel regulatory mechanism of BRMS1 by Cul3-SPOP complex is important for breast cancer progression. PMID: 22085717 SATB1 and BRMS1 might play an important role in the development and lymph node metastasis of ovarian cancer. PMID: 21355308 possible link between BRMS1 expression and apoptosis in human breast cancer through a relationship with the expression of genes belonging to the X-chromosome RBM family. PMID: 21737612 the enigmatic complexities of BRMS1-mediated metastasis suppression PMID: 21827753 The expression of BRMS1 protein in supraglottic cancer is significantly decreased. Expression has a close relationship with pathologic differentiation and clinical stage and cervical lymph node metastasis. PMID: 19621595 Expression of BRMS1 mRNA in supraglottic cancer is lower than that in adjacent normal mucosa. PMID: 18533556 BRMS1 expression was decreased in metastatic melanomas, which resulted in deficient suppression of angiogenesis and contributed to melanoma progression. PMID: 20935672 Study observed that SNX6 increases BRMS1-dependent transcriptional repression. Moreover, over-expression of SNX6 was capable of diminishing trans-activation in a dose-dependent manner. PMID: 20830743 Patients with high levels of expression of BRMS1 mRNA have a better prognosis than those with low expression. PMID: 17085653 ING4 is induced by BRMS1 and that it inhibits melanoma angiogenesis by suppressing NF-kappaB activity and IL-6 expression. PMID: 21056991 BRMS1 expression in breast cancer cells induced reorganization of F-actin and caused alteration in cytoarchitectures (cell topography and ultrastructure). PMID: 20083343

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.